Table 2.
Performance of candidate proteins
| Antibody | Gene | Assay | Correlation (Rho) | p‐value | Technical CV | Trend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Set‐1 | Set‐2 | Set‐1 | Set‐2 | Set‐1 | Set‐2 | Set‐1 | Set‐2 | |||
| HPA029018 | AMFR | 1 | 0.95 | 0.93 | 0.02 | 0.00005 | 5% | 2% | − | − |
| 2 | 0.01 | 0.00002 | 3% | 2% | − | − | ||||
| HPA029473 | PAEP | 1 | 0.94 | 0.95 | 0.06 | 0.0001 | 3% | 5% | − | − |
| 2 | 0.02 | 0.00002 | <1% | 5% | − | − | ||||
| HPA034660 | NOTO | 1 | 0.85 | 0.80 | 0.03 | 0.005 | 7% | 9% | + | + |
| 2 | 0.08 | 0.004 | 7% | 4% | + | + | ||||
Antibodies discriminating between cases and controls are summarized for repeated assays, including the trends of increased (+) or decreased (−) intensity levels in relation to the osteoporosis patient group.